Introduction
In the Polish population, according to the WOBASZ II study, the prevalence of hypertension in adults above 20 years of age is 46% and 40% and the prevalence of dyslipidemia is 70% and 64.3% in men and women, respectively [1, 2] .
In the Polish NATPOL 2011 study, in the general population aged 18 to 79 years, the prevalence of hypercholesterolemia was estimated at 61.1% and the efficacy of treatment (achieving TC <4.9 mmol/l) at 10.9% [3] . In POLFOKUS, another Polish study, elevated level of LDL cholesterol was observed in 49.2%, 61.6% and 61.5% patients with controlled, uncontrolled and resistant hypertension respectively [4] . The prevalence of other modifiable risk factors for cardiovascular disease in the WOBASZ II study population was described earlier [5] [6] [7] [8] .
The Framingham study showed that hypertension increases the incidence of CVD two to three timeswith the highest risk of stroke, heart failure and all forms of coronary heart disease (CHD): angina pectoris, myocardial infarction, sudden cardiac death. In patients aged systolic and diastolic blood pressure of 20/10 mmHg [9] . A relationship with CVD risk was seen in a wide range of total cholesterol (TC) and low-density lipoprotein (LDL-C) concentrations. This applies to men and women, both with and without diagnosed CVD [10] .
It has been proved that changes in systolic blood pressure in the range of 110-170 mmHg are associated with an approximately six-fold increase in CHD risk. Similarly, an increase in total cholesterol level in the range of 4.0-8.0 mmol/l results in an approximately eight-fold increase in the risk of CHD. The blood pressure increase in the range of 110/70 to 170/105 also increases the risk of stroke nearly eight times [11] . The implementation of antihypertensive treatment reduces the risk of CHD by approximately 25% [12] . The inclusion of lipid-lowering treatment in hypertension patients reduces the residual risk of CHD by more than 35% [13] , as confirmed by the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) [14] and the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) [15] .
Patients with multiple CVD risk factors are at higher risk of incident CVD than persons exposed to only one risk factor. The CVD risk resulting from concomitant hypertension and hypercholesterolemia is typically greater than the sum of risk from individual exposure to hypertension or hypercholesterolemia alone [16, 17] . It was found that in hypertension patients with concomitant hyperlipidemia, the risk of CVD increases twice, and in patients with normal cholesterol levels, the coexistence of hypertension results in a 3-fold increase in the risk of CVD [14] . In people with a systolic pressure of 195 mmHg and total cholesterol 8.5 mmol/l increases the CVD as much as 9-fold [18. Data on men aged 35-64 from the POL-MONICA study showed that the coexistence of hypertension and hypercholesterolemia increases the risk of death caused by coronary heart disease over 4.5 times [19] .The assessment of the overall cardiac risk can be made using the SCORE tables. E.g. in the Polish population, a non-smoker 70-year-old male with SBP 180mmHg and TC 8mmol/l has a 50% risk of cardiovascular death within 10 years and respectively with SBP 120mmHg and TC 4 mmol/l only 10% [20] .
Results of the analyses on the Polish population published so far do not indicate in what extent exposure to hypertension and hypercholesterolemia occurs in the same persons.
The objectives of the study were: 1) to assess the prevalence of comorbid hypertension and hypercholesterolemia in participants of the nationwide WOBASZ II study 2) to assess the prevalence of hypercholesterolemia in the Polish hypertensive population 3) to evaluate blood pressure and cholesterol level control among patients with hypertension and hypercholesterolemia, and 4) to assess the factors related with the control.
Patients and method
The WOBASZ II study was a cross-sectional survey conducted in 2013-2014 in 6,170 persons (3,410 women and 2,760 men) from 16 voivodships (108 communes). The reporting rate was 45.5%. The sampling method used a three-stage scheme, stratified by voivodship, commune category, and sex. The study conduct was approved by the Ethics Committee at the Institute of Cardiology in Warsaw. Each respondent was informed in writing about the purpose of the study and the range of activities (including blood pressure measurements and blood collection for clinical chemistry tests). The study methods have been presented in detail previously [21] . Blood pressure measurements were taken during one visit, three times, in a sitting position, in accordance with ESH/ESC 2013 (European Society of Cardiology/European Society of Hypertension) [22] and PTNT 2015 (Polish Society of Hypertension) [23] guidelines. An UA-631(AND Co., Tokyo, Japan) automatic device was used. The mean of the second and third measurements was used for analysis. Clinical chemistry tests were performed at the Central Laboratory "Diagnostyka" at the Institute of Cardiology in Warsaw, which has been certified by the CDC (Centre for Disease Control -Lipid Standardization Program) in Atlanta and has the European quality certificate RIQAS (Random International Quality Assessment Scheme). The sequence of procedures was as follows: first, blood pressure measurements were performed, then a survey was taken, and finally, blood was collected for clinical chemistry tests. Details of the methodology for measuring blood pressure, blood collection and clinical chemistry tests have been described earlier [1, 2] .
The following definitions were used: hypertension was defined as the presence of systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg or use of blood pressure-lowering medication (regular for the last two weeks). Hypercholesterolemia was diagnosed if total cholesterol (TC) levels were 5 mmol/l or higher, or Low-Density Lipoprotein-Cholesterol (LDL-C) levels were 3 mmol/l or higher, or the participant was taking a lipid-lowering medication (regular for the last two weeks). Treated hypertension was defined as the proportion of patients with hypertension who reported taking medication for high BP (affirmative response to the question: "Have you taken these medicines regularly during the last two weeks?"). Treated hypercholesterolemia was defined as the proportion of patients who reported taking medication for high cholesterol level (affirmative response to the question: "Have you taken these medicines regularly during the last two weeks?"). Controlled hypercholesterolemia was defined as the proportion of patients with hypercholesterolemia who had TC <5 mmol/l and LDL-C <3 mmol/l for people with intermediate or low cardiovascular risk; LDL-C <2.5 mmol/l for people with high CVD risk; LDL-C <1.8 mmol/l for people with very high CVD risk. (The target treatment thresholds have been adopted according to the risk category based on the European guidelines for CVD prevention in clinical practice (version 2016) [24] . Controlled hypertension was defined as the proportion of patients with hypertension who had SBP <140 mmHg and DBP <90 mmHg. Low CVD risk according to the Systematic COronary Risk Evaluation (SCORE): <1%. Intermediate CVD risk according to SCORE: ≥1 and <5%. High CVD risk according to SCORE: ≥5 and <10%.
Very high CVD risk according to SCORE: ≥10%. Diabetesaffirmative response to the question: "Have you ever been diagnosed with diabetes?" or the participant taking a hypoglycemic medication (regular for the last two weeks). Smokingat least one cigarette per day. Comorbid CVDpreviously diagnosed coronary artery disease, past myocardial infarction, myocardial revascularization, previous stroke, peripheral atherosclerosis.
Physical activityat least 30 min of uninterrupted activity, e.g., a walk, gymnastic exercises at least 4 days/week.
Alcohol drinkers -affirmative response to the question: "Have you drunk any vodka, wine or beer in the last 12 months at least once?" High educationmore than vocational education.
Obesity was defined as BMI ≥ 30kg/m 2 , overweight when BMI was 25-30 kg/m 2 and normal weight when BMI<25kg/m 2 . Incomeincome per person in the household > PLN 1,000 (> EUR 250).
Statistical analyses
Continuous variables such as blood pressure values, age were presented using the arithmetic mean, and 95% confidence interval (95%CI), TC, LDL, HDL-C, TG presented using median and (95%CI). Qualitative variables were presented as percentages and 95% CI. Crude prevalence of hypertension and hypercholesterolemia, and the prevalence of both hypertension and hypercholesterolemia control were described as percentages, and 95% CI for the following age ranges 20-49, 50-59, 60-69, 70-79 and over 80 years. The results were standardized [25] for age of the Polish population based on data from the Central Statistical Office report of 31/12/2014. The standardization method has been described in detail earlier [21] . The prevalence of the analyzed features was compared using the chi-square test for trend. The influence of various parameters (age, sex, BMI, diabetes, HDL-C, TG, smoking, alcohol consumption, education, physical activity, co-existing CVD, marital status, SCORE, number of visits and marital status ) on the control of blood pressure, hypercholesterolemia and simultaneous control of both blood pressure and hypercholesterolemia was evaluated by 
Results
The analysis included 5,939 participants aged 19-99 years (2,647 men and 3,292 women). 231 people with no blood pressure or no cholesterol levels were excluded from the analysis Mean age was 49.516.3 (for men 48.916.3, for women 50.016.3).
In whole WOBASZ II population hypertension was found in 2,784 (crude data 46,9%) persons (1,365 men and 1,419 women). Mean age was 58.413.9 years (men: 55.8 women: 60.9).
Comorbid hypertension and hypercholesterolemia was found in 2,037 persons (982 men and 1,055 women). Mean age was 58.812.9 years (men: 56.1 women: 60.5).
Descriptive statistics of the study group are summarized in Table 1 and in women 31% (95%CI: 29.1-32.9). Table 3 .
Age-standardized prevalence of hypercholesterolemia in patients diagnosed with hypertension was 69.7% (95% CI: 65.9-73.4) in the entire study sample, 70% (95% CI: 64.9-75.2) in men, and 68.6% (95% CI: 63.1-74.2) in women. The highest prevalence (crude data) was observed in women aged 50-59 years (83.3% [95% CI: 79.6-87.1]) and in men aged 60-69 years (76.2% [95% CI: 71.9-80.6]). Table 4 .
Among patients with coexisting hypertension and hypercholesterolemia, the highest control rate of hypertension, hypercholesterolemia and both hypertension and hypercholesterolemia (crude data) was seen in the oldest subjects above 80 years of age (37.7%, 29.2%, and 17%, respectively). Age-standardized control of hypertension, hypercholesterolemia, and both hypertension and hypercholesterolemia in the entire sample (age range of 19 to 99 years) was 24.3%, 11.2%, and 5.4%, respectively (Table 5) .
Age, comorbid diabetes, comorbid CVD, frequent medical visits, SCORE<5% were positively associated with a control of hypertension, hypercholesterolemia, and both. Female sex, obesity, income above EUR 250 per person in the household were not associated with hypercholesterolemia control, but related with control of hypertension and a control of both hypertension and hypercholesterolemia. Education higher than vocational was associated only with improvement in hypertension control. Conversely, smoking was associated with worse control of hypertension, hypercholesterolemia, and both conditions. BMI <25 kg/m 2 , alcohol consumption, and SCORE >=10% were inversely associated with hypertension control ( Table 6 ). 
Discussion
Our results suggest that about one third of the adult population have comorbid hypertension and hypercholesterolemia. Control of hypertension in this group appeared similar to the control in general population but control of hypercholesterolemia was better than in general population [1, 2] . Nevertheless, proportion of persons with both conditions controlled was only about 5%.
Considering the more stringent thresholds of antihypertensive treatment in accordance with the guidelines of ESH 2018 [26] and PTNT 2019 [27] (for patients below 65 years old, the target pressure below 130/80 mmHg, between 65 and 85 -below 140/80 mmHg and over 80below 150/80 mmHg) blood pressure control in the WOBASZ II population would decrease from 23% to approximately 14% and simultaneous control of hypercholesterolemia and blood pressure would only reach 3.5% of patients.
Achieving treatment targets for hypertension or hypercholesterolemia was more frequent in women, high educated participants, non-smokers, persons with comorbid CVD or diabetes and in participants who attended medical visits more frequently.
In the interpretation of the results obtained some caution is recommended mainly due to relatively low (approximately 45.5%) participation rate which could have affected the representativeness of the sample. In previous WOBASZ II analysis it was found that regional differences in the prevalence of hypercholesterolemia were related to the participation rate (0.4% increase in the percentage of people with hypercholesterolemia per 1% increase in reporting rate) [2] . Such relationship was not observed in case of hypertension prevalence [1] .
Moreover, our participation rate was similar to that recorded in other European studies, e.g. the EHES study conducted in 2009-2012, in which the reporting rate ranged from 16% to 57% in men and from 31% to 74% in women [28] . However, it is likely that low response rate although might have contributed to some underestimation in the prevalence rates, but affected less the relationships studied [29, 30] .
Further, cross-sectional study design does not allow to address the problem of causality.
Although multivariate models allow to control the effect of important covariates, residual confounding is still possible.
Nevertheless, there are strengths of the study. One would be that in contrast to most of the evidence collected in patients from the clinics, our study involved a large, nationwide sample.
The other is that research team applied standardized research procedures to ensure highest possible data quality.
Comparing our results to a large epidemiological study conducted in the USA in 2005-2010, NHANES, we found that the US participants more than four times more often (45.4% vs.
11.2%) achieved the goal of lipid-lowering therapy and control of both hypertension and
hypercholesterolemia was six times more common than in our study (30.7% vs. 5.4%) [31] .
These comparison might have indicated the gap in the effectiveness of risk factors control between Poland and USA. However, observed difference could also be explained by larger prevalence of obesity, diabetes and lower prevalence of smoking in the NHANES sample.
According to our results these factors seem to improve hypertension and hypercholesterolemia control.
The i-SEARCH study, conducted in more than 17,000 patients from 26 countries with treated hypertension, found lower prevalence of hypercholesterolemia (average 49%) than observed in our study. However, there was large variation in hypercholesterolemia prevalence in different regionsthe lowest prevalence was observed in Southern Europe (43.3%) and Asia (43.1%) and the highest in North America (64.4%), the Middle East (56.1%) and Northern Europe (53%) [32] . In the Polish POSTER study (Therapeutic strategies in poorly controlled hypertension in outpatient setting in Poland), which enrolled 8,766 patients with poorly controlled hypertension, the prevalence of hypercholesterolemia was estimated at 64.8% [33] .
Our results are in accordance with findings from Polish part of the EUROASPIRE IV study, which showed better control of hypertension and hypercholesterolemia in patients after hospitalization due to CHD [34] compared to the findings from general population [1, 2] .
In our study, in participants with comorbid hypertension and hypercholesterolemia, we found that blood pressure control was low and comparable to the general population (23% vs. 24 .3%), whereas hypercholesterolemia control was nearly twice higher than in the general population (11.2% vs. 6%) [1] . Many patients with hypertension and hypercholesterolemia present low compliance and adherence to medical advising and do not achieve the therapeutic goals, which has significant clinical and economic consequences [35] [36] [37] . Recently, a promoted way of improving blood pressure and hypercholesterolemia control could be use of a polypill -a single tablet containing a combination of several drugs (including antihypertensive and lipid-lowering agents) with proven efficacy and cardioprotective effect.
It is suggested that in the population above 55 years of age such a combination product could prevent as many as 80% of cardiovascular events [38] [39] [40] [41] [42] . Although combination pills containing both antihypertensive and lipid-lowering drugs exist, they are not often used in clinical practice. Their use on a larger scale could contribute to an improvement in blood pressure control, as well as to the achievement of cholesterol targets; for this reason, the position of combination products has recently been strengthened in the European guidelines for hypertension and hypercholesterolemia treatment [43, 44] .
It seems that introduction of polypill could contribute to solve a problem of not undertaking or discontinuing of treatment (13% of hypertension and 17% of hypercholesterolemia) or a problem of the use of ineffective doses (23% of hypertension and 23% of hypercholesterolemia) [1, 2] . Still the final effect would be related largely to the level of motivation of patients to change the lifestyle (diet, physical activity) and keep the long term treatment regime. However, the largest public health problem in Poland is poor detection of risk factors, Over 60% of people with hypercholesterolemia and about 40% with hypertension are not aware of the condition [1, 2] , which substantially limits the potentials of the available treatments.
Conclusions
Hypertension and hypercholesterolemia were observed in one third of the Polish population (included in WOBASZ II study). Only 5,4% have both risk factors controlled. After adjustment for covariates, female gender, non-smoking, comorbid CVD or diabetes, frequency of medical visits and high education, appeared to increase the proportion of controlled hypertension or hypercholesterolemia.
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